Pioneering New Methods Of Drug Manufacture

Main Category: Pharma Industry / Biotech Industry
Article Date: 12 Nov 2009 - 3:00 PST

email to a friend   printer friendly   view / write opinions

Engineers at the University of Leeds have developed a simple technology which can be used in existing chemical reactors to ensure "right first time" drug crystal formation.

Ensuring drug crystals are formed correctly is crucial to their efficacy and the efficiency of pharmaceutical manufacturers' operations. Using self-assembled monolayers, the team has been able to show that crystals form into their desired product form with the correct shape and particle structure, without the usual problems of polymorphism which results in huge losses to the pharmaceutical sector each year.

"If you imagine the way that oil sits on top of water, that's similar to how the monolayer works," says Professor Kevin Roberts of University's Faculty of Engineering. "We've shown that we can produce a well-defined crystal structure using a self-assembled monolayer bound onto a metal substrate within a regular reactor. This is exciting stuff, because it's a relatively simple system, but could make a huge difference in the efficiency of drug manufacture."

One of the first stages of the crystallisation process is called nucleation. During nucleation, particles are introduced into a reactor to encourage the formation of crystals. However, the way in which this is currently carried out is difficult to control and can often lead to the wrong shape, size or structure of drug crystal, something which affects the usefulness and efficacy of the compound.

The new system proven to work by the Leeds team, working alongside Ana Kwokal from Croatian pharmaceutical company PLIVA, has shown that introducing a self-assembled monolayer - a layer of self-organising molecules that is attractive to the substance being crystallised - into a reactor enables consistent crystal formation.

Professor Roberts says: "Because this is a really simple solution to ensuring consistent crystallisation, it has huge potential commercially. Our next steps are to make sure it's just as efficient on an industrial scale."

This work draws on previous research and experimental systems developed through the Chemicals Behaving Badly II initiative, an Engineering and Physical Sciences Research Council (EPSRC) programme which includes universities and industrial partners.

Source: Clare Elsley
University of Leeds